Intellectual Property Rights and Access to Innovation: Evidence from Trips

@article{Kyle2014IntellectualPR,
  title={Intellectual Property Rights and Access to Innovation: Evidence from Trips},
  author={Margaret Kyle and Yi Qian},
  journal={Kauffman: Large Research Projects (Topic)},
  year={2014}
}
  • M. KyleYi Qian
  • Published 1 December 2014
  • Economics, Medicine
  • Kauffman: Large Research Projects (Topic)
We examine the effect of pharmaceutical patent protection on the speed of drug launch, price, and quantity in 60 countries from 2000-2013. The World Trade Organization required its member countries to implement a minimum level of patent protection within a specified time period as part of the TRIPS Agreement. However, members retained the right to impose price controls and to issue compulsory licenses under certain conditions. These countervailing policies were intended to reduce the potential… 

Do Patents Work? Thickets, Trolls and Antibiotic Resistance

This paper connects ideas from recent literature on the economics of intellectual property (IP) to address the question: Did the strengthening and broadening of IP rights from important patent policy

Patents, trade and medicines: past, present and future

Abstract This article analyzes the spread of intellectual property in trade agreements. We explain how the integration of intellectual property with international trade rules led to the globalization

The hidden cost of low prices: limited access to new drugs in India.

It is concluded that modest patent and regulatory reform could bring the faster availability of a wider range of new drugs in India with limited impact on prices--a trade-off that merits greater policy attention.

The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India

In 2005, as the result of a World Trade Organization mandate, India began to implement product patents for pharmaceuticals that were compliant with the 1995 Trade-Related Aspects of Intellectual

Does Regulation Drive International Research Cooperation? Evidence from the Pharmaceutical Sector

To what extent is an increased stringency of the Intellectual Property Rights (IPR) system apt to stimulate research cooperation between developed and emerging economies? To address this question, we

Intellectual Property Rights and Innovation: Evidence from Health Care Markets

A long theoretical literature has analyzed optimal patent policy design, yet there is very little empirical evidence on a key parameter needed to apply these models in practice: the relationship

Value Appropriation and New Product Pricing: A Study of New Prescription Drugs

Value appropriation, or a firm’s ability to collect economic rents from its offerings, tools can erect barriers to competition and influences firm profitability. Patent protections are widely used

References

SHOWING 1-10 OF 35 REFERENCES

Do Patents Matter?: Empirical Evidence after GATT

Since the late 1980s the global intellectual property rights (IPR) system has been strengthening dramatically as much of the developing world introduces patent protection for new drug products. This

Investments in Pharmaceuticals Before and After TRIPS

Abstract The TRIPS Agreement, which specifies minimum levels of intellectual property protection for countries in the WTO, has increased levels of patent protection around the world. Using variation

Diffusion of New Drugs in the Post-TRIPS Era

Abstract We examine the international diffusion of new drugs under the post-TRIPS intellectual property rights regime. Even after controlling for drug characteristics and variation in national health

The hidden cost of low prices: limited access to new drugs in India.

It is concluded that modest patent and regulatory reform could bring the faster availability of a wider range of new drugs in India with limited impact on prices--a trade-off that merits greater policy attention.

The Role of Firm Characteristics in Pharmaceutical Product Launches

This paper examines the determinants of new pharmaceutical launches since 1980 in the G7 nations using discrete-time hazard models. Despite the obvious incentive to amortize the large sunk costs of

The Market Impacts of Pharmaceutical Product Patents in Developing Countries: Evidence from India

In 2005, as the result of a World Trade Organization mandate, India began to implement product patents for pharmaceuticals that were compliant with the 1995 Trade-Related Aspects of Intellectual

DETERMINANTS OF PATENT RIGHTS : A CROSS-NATIONAL STUDY

The Impact of Stronger Property Rights in Pharmaceuticals on Innovation in Developed and Developing Countries

We use dynamic panel data regressions to investigate whether the strength of a country’s patent protection for pharmaceuticals is associated with more pharmaceutical patenting by its residents and

The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s

The results indicate that countries with lower expected prices or smaller expected market size have fewer launches and longer launch delays, controlling for per capita income and other country and firm characteristics.

Do Stronger Intellectual Property Rights Increase International Technology Transfer? Empirical Evidence from U.S. Firm-Level Panel Data

One of the alleged benefits of the recent global movement to strengthen intellectual property rights (IPRs) is that such reforms accelerate transfers of technology between countries. The paper